-
Use of ctDNA Guides Panitumumab Rechallenge Efficacy in Colorectal Cancer. Cancer Discov. (IF 38.272) Pub Date : 2022-08-12
Use of ctDNA can effectively guide panitumumab rechallenge in metastatic colorectal cancer.
-
Multicellular Dynamics Associated with Clinical Outcome Were Discovered in PDAC. Cancer Discov. (IF 38.272) Pub Date : 2022-08-12
Multicellular dynamics, including neoadjuvant treatment-associated changes, were uncovered in PDAC.
-
The BEHAV3D Platform Demonstrates Cellular Immunotherapy Modes of Action. Cancer Discov. (IF 38.272) Pub Date : 2022-08-12
An organoid-based, 3D imaging-transcriptomic platform was developed to investigate immunotherapy modes of action.
-
Neuronal Mechanisms Drive Whole Brain Invasion in Glioblastoma. Cancer Discov. (IF 38.272) Pub Date : 2022-08-12
Whole brain invasion of glioblastoma (GB) is driven by single GB cells with neuronal features.
-
President's Pick for NCI: Monica Bertagnolli, MD. Cancer Discov. (IF 38.272) Pub Date : 2022-08-12
President Joe Biden has chosen Monica Bertagnolli, MD, a renowned surgical oncologist, group chair of the Alliance for Clinical Trials in Oncology, and former president of the American Society of Clinical Oncology, to be the 16th director of the NCI. She will be the first woman to hold the position since the agency's founding in 1937. The news was greeted with excitement and praise from cancer researchers
-
Adjuvant Atezolizumab Holds Its Own in NSCLC. Cancer Discov. (IF 38.272) Pub Date : 2022-08-10
According to new data from the phase III IMpower010 trial, adjuvant atezolizumab improves overall survival compared with best supportive care for some patients with operable non-small cell lung cancer. These results build on previous study findings, in which the immune checkpoint inhibitor, given after surgery and adjuvant chemotherapy, was shown to significantly decrease the likelihood of disease
-
BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05 James D Phelan,Thomas Oellerich
BCL10, a key activator of NF-κB downstream of oncogenic B-cell receptor signaling, is mutated in nearly 40% of the BN2/C1 genetic subtype of diffuse large B-cell lymphoma, but how these mutations function to augment signaling and their relevance to targeted precision medicine agents remains unclear. In this issue of Cancer Discovery, Xia and colleagues demonstrate distinct mechanisms of oncogenic signaling
-
Hiding in Plain Sight: A Novel Microbial Driver for Colorectal Cancer? Cancer Discov. (IF 38.272) Pub Date : 2022-08-05 Tejeshwar Jain,Vikas Dudeja
In this issue of Cancer Discovery, Drewes and colleagues demonstrate a surprising role for the common gut pathogen Clostridioides difficile in driving colorectal cancer in preclinical models through the bacterial toxin-dependent reprogramming of the epithelial and immune compartments. See related article by Drewes et al., p. 1873 (3).
-
Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05 Anne-Gaelle Goubet,Leonardo Lordello,Carolina Alves Costa Silva,Isabelle Peguillet,Marianne Gazzano,Maxime Descartes Mbogning-Fonkou,Cassandra Thelemaque,Cedric Lebacle,Constance Thibault,Francois Audenet,Geraldine Pignot,Gwenaelle Gravis,Carole Helissey,Luca Campedel,Morgan Roupret,Evanguelos Xylinas,Idir Ouzaid,Agathe Dubuisson,Marine Mazzenga,Caroline Flament,Pierre Ly,Virginie Marty,Nicolas Signolle
Biomarkers guiding the neoadjuvant use of immune checkpoint inhibitors (ICBs) are needed for patients with localized muscle invasive bladder cancers (MIBC). Profiling tumor and blood samples, we found that follicular helper CD4+ T cells (TFH) are among the best therapeutic targets of pembrolizumab correlating with progression-free survival. TFH were associated with tumoral CD8 and PD-L1 expression
-
Collagen I Homotrimers Promote PDAC Growth and Impact Immunity. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Cancer cell-derived Col1 homotrimers regulate the PDAC microbiome and block T-cell infiltration.
-
PI3K-AKT Inhibits PANK4 to Promote De Novo Synthesis of Coenzyme A. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
AKT inhibits the metabolic enzyme PANK4 to promote the de novo synthesis of coenzyme A (CoA).
-
The Oncolytic Virus G47Δ Shows Efficacy and Safety in Glioblastoma. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Survival benefit and a manageable safety profile were observed with G47Δ in patients with glioblastoma.
-
Checkpoint Inhibitors Can Up Heart Harm. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Patients on ICI therapy rarely experience life-threatening myocarditis, but little is currently known about the risk of other major adverse cardiac events (MACE) in this population. A retrospective study finds that 10% of patients, mostly with advanced cancers, experience MACE, with those with preexisting poor cardiovascular health being at greater risk.
-
Genetic Risk Score Improves Prediction of Severe Obesity after Childhood Cancer. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Addition of genetic risk score to prediction models improves obesity risk prediction in adult survivors of childhood cancer.
-
Specific KRAS-Mutant Cancers Are Sensitive to Inhibition of V-type ATPases. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
249C was identified as a selective Ras-mutant cytotoxic agent that binds to and inhibits V-ATPase.
-
IL6 Signaling Enables Survival of Chromosomally Instable Cancer Cells. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
The cGAS-STING axis drives IL6 signaling to enable survival despite chromosomal instability (CIN).
-
Calreticulin Mutant-Induced MHC-I Skewing Supports Heteroclitic Peptide Vaccine Use. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Immune-mediated skewing of MHC-I allele frequency occurs in calreticulin-mutant myeloproliferative neoplasms.
-
GPRC5D-Directed CAR Yields 100% Response Rate. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Patients with refractory or relapsed multiple myeloma usually develop resistance to the two approved BCMA-targeting chimeric antigen receptor (CAR) T cells. A preliminary study of a new CAR T-cell therapy that zeroes in on the GPRC5D protein on multiple myeloma cells suggests that this approach is safe and effective. All 10 patients treated with the GPRC5D-targeting cells showed responses.
-
Androgen Receptor Signaling Reduces Male Antitumor CD8+ T-cell Activity. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
CD8+ T cell-intrinsic androgen receptor (AR) signaling promotes sex-biased antitumor immunity.
-
Resistance to BRAF/MEK Inhibition in Melanoma Is Mediated by the Androgen Receptor. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Androgen receptor (AR) expression increases upon BRAF/MEK inhibitor treatment, promoting resistance.
-
A Response Prediction Scheme Was Created Using Data from the I-SPY2 Trial. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
The developed RPS-5 response prediction scheme was more predictive of pathologic complete response.
-
ZBP1-Driven Necroptosis Potentiates Immunotherapy and Is Blocked by ADAR1. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
ADAR1 binds endogenous Z-RNA and masks the immunotherapeutic potential of ZBP1-induced necroptosis.
-
Induction of T- and NK-cell Activity Improves Cancer Vaccine Efficacy. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
A cancer vaccine targeting MICA/B was developed that induces T-cell and NK-cell activation.
-
XIST Loss Promotes Mediator Activity to Enhance Tumorigenic Potential. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
XIST controls homeostasis in mammary stem cells, balancing self-renewal and differentiation.
-
The impact of inflammation-induced tumor plasticity during myeloid transformation. Cancer Discov. (IF 38.272) Pub Date : 2022-08-04 Anna Yeaton,Geraldine Cayanan,Sanam Loghavi,Igor Dolgalev,Emmett M Leddin,Christian E Loo,Hedieh Torabifard,Deedra Nicolet,Jingjing Wang,Kate Corrigan,Varvara Paraskevopoulou,Daniel T Starczynowski,Eric Wang,Omar Abdel-Wahab,Aaron D Viny,Richard M Stone,John C Byrd,Olga A Guryanova,Rahul M Kohli,G Andres Cisneros,Aristotelis Tsirigos,Ann-Kathrin Eisfeld,Iannis Aifantis,Maria Guillamot
Clonal hematopoiesis (CH) is an aging-associated condition characterized by the clonal outgrowth of mutated pre-leukemic cells. Individuals with CH are at an increased risk of developing hematopoietic malignancies. Here, we describe a novel animal model carrying a recurrent TET2 missense mutation, frequently found in CH and leukemic patients. In a fashion similar to CH, animals show signs of disease
-
Impaired proteolysis of non-canonical RAS proteins drives clonal hematopoietic transformation. Cancer Discov. (IF 38.272) Pub Date : 2022-07-29 Sisi Chen,Rahul S Vedula,Antonio Cuevas-Navarro,Bin Lu,Simon J Hogg,Eric Wang,Salima Benbarche,Katherine Knorr,Won Jun Kim,Robert F Stanley,Hana Cho,Caroline Erickson,Michael Singer,Dan Cui,Steven Tittley,Benjamin H Durham,Tatiana S Pavletich,Elise Fiala,Michael F Walsh,Daichi Inoue,Sebastien Monette,Justin Taylor,Neal Rosen,Frank McCormick,R Coleman Lindsley,Pau Castel,Omar Abdel-Wahab
Recently, screens for mediators of resistance to FLT3 and ABL kinase inhibitors in leukemia resulted in the discovery of LZTR1 as an adaptor of a Cullin-3 RING E3 ubiquitin ligase complex responsible for degradation of RAS GTPases. In parallel, dysregulated LZTR1 expression via aberrant splicing and mutations were identified in clonal hematopoietic conditions. Here we identify that loss of LZTR1, or
-
Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer. Cancer Discov. (IF 38.272) Pub Date : 2022-07-29 Yong Gu Lee,Puneeth Guruprasad,Guido Ghilardi,Raymone Pajarillo,Christopher Tor Sauter,Ruchi Patel,Hatcher J Ballard,Seok Jae Hong,Inkook Chun,Nicholas Yang,Kimberly V Amelsberg,Katherine D Cummins,Jakub Svoboda,Saar Gill,Elise A Chong,Khrystyna North,Sarah E Church,Joseph A Fraietta,Wan-Jung Chang,Simon F Lacey,Xueqing Maggie Lu,Yunlin Zhang,Kanupriya Whig,David C Schultz,Sara Cherry,James Gerson
Chimeric Antigen Receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two-thirds of patients fail this treatment. Resistance to apoptosis is a key feature of cancer cells that associates with treatment failure. In 87 NHL patients treated with anti-CD19 CART, we found that chromosomal alteration of BCL-2
-
Serine Acylation Allows for Therapeutic Inhibition of K-Ras(G12S) Mutations. Cancer Discov. (IF 38.272) Pub Date : 2022-07-29
Selective inhibitors of K-Ras(G12S) mutations were developed that suppress oncogenic signaling.
-
Pyruvate Metabolism Enables Antitumor Succinate Signaling in CD8+ T Cells. Cancer Discov. (IF 38.272) Pub Date : 2022-07-29
Tumor-derived lactate disrupts pyruvate metabolism and cytotoxic function of antitumor CD8+ T cells.
-
Plasma L-Arginine Predicts Clinical Response to Immune Checkpoint Inhibitors. Cancer Discov. (IF 38.272) Pub Date : 2022-07-29
Baseline plasma L-Arginine (ARG) levels can predict response to immune checkpoint inhibitors (ICI).
-
Deep ctDNA Profiling Demonstrates Genomic Features of Metastatic Disease. Cancer Discov. (IF 38.272) Pub Date : 2022-07-29
Multiple dominant somatic populations are present in ctDNA, with AR alterations driving treatment resistance.
-
Pro- versus Antitumor γδ T-cell Activity Is Distinguished by TCR-Vγδ Use. Cancer Discov. (IF 38.272) Pub Date : 2022-07-29
Contrasting γδ T-cell function in tumors is dependent on TCR-Vγδ gene usage in both humans and mice.
-
AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discov. (IF 38.272) Pub Date : 2022-07-27 Ashish Noronha,Nishanth Belugali Nataraj,Joo Sang Lee,Benny Zhitomirsky,Yaara Oren,Sara Oster,Moshit Lindzen,Saptaparna Mukherjee,Rainer Will,Soma Ghosh,Arturo Simoni-Nieves,Aakanksha Verma,Rishita Chatterjee,Simone Borgoni,Welles Robinson,Sanju Sinha,Alexander Brandis,D Lucas Kerr,Wei Wu,Arunachalam Sekar,Suvendu Giri,Youngmin Chung,Diana Drago-Garcia,Brian P Danysh,Mattia Lauriola,Michelangelo Fiorentino
Anti-cancer therapies have been limited by emergence of mutations and other adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone factors that allow for continuous replication at the cost of mutagenesis. We investigated whether treatment of lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. In cycling drug-tolerant persister (DTP) cells
-
Implantable Microdevices Identify Microenvironment-Modulating Drug Combinations. Cancer Discov. (IF 38.272) Pub Date : 2022-07-22
Use of an implantable microdevice identified drug combinations that improve therapeutic efficacy in tumors.
-
Novel Germline Loci Are Associated with Clonal Hematopoiesis Risk. Cancer Discov. (IF 38.272) Pub Date : 2022-07-22
Novel germline loci were associated with the risk of clonal hematopoiesis (CH) within the UK Biobank.
-
Progression-Free Survival of LM Is Improved by Proton Craniospinal Irradiation. Cancer Discov. (IF 38.272) Pub Date : 2022-07-22
pCSI improved central nervous system progression-free survival of LM as compared to standard of care.
-
Cell Adhesion Signaling Regulates Cancer Stem Cell Dormancy after Chemotherapy. Cancer Discov. (IF 38.272) Pub Date : 2022-07-22
A 4D live imaging system identified LGR5+ p27+ cancer stem cells that persist after chemotherapy and contribute to disease relapse.
-
Arginine Depletion plus GCN2 Inhibition Sensitizes HCC Cells to Senolytic Therapies. Cancer Discov. (IF 38.272) Pub Date : 2022-07-22
Combined arginine depletion, GCN2 kinase inhibition, and senolytic therapy reduces HCC growth.
-
Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. Cancer Discov. (IF 38.272) Pub Date : 2022-07-20 Paolo Tarantino,Giuseppe Curigliano,Sara M Tolaney
The confirmation of the HER2-low paradigm is expected to have a major impact in breast oncology. About half of all breast cancers harbor HER2-low expression, which can be targeted with the anti-HER2 antibody-drug conjugate trastuzumab deruxtecan (T-DXd), leading to a relevant survival benefit in the metastatic setting. Given this observation, treatment algorithms for both hormone receptor-positive
-
Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma. Cancer Discov. (IF 38.272) Pub Date : 2022-07-19 Youpei Lin,Lihua Peng,Liangqing Dong,Dongbing Liu,Jiaqiang Ma,Jian Lin,Xiaofang Chen,Penghui Lin,Guohe Song,Mao Zhang,Yuming Liu,Junhua Rao,Chen Wei,Ye Lu,Shu Zhang,Guangyu Ding,Zhenyu Peng,Haorong Lu,Xiaoying Wang,Jian Zhou,Jia Fan,Kui Wu,Qiang Gao
Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and extremely high mortality rate. Here, we performed WES, RNA-seq, TCR-seq and multiplexed immunofluorescence on 207 tumor regions from 45 iCCA patients. Over half of iCCA displayed intratumoral heterogeneity of immune infiltration, and iCCA were classified into sparsely, heterogeneously, and highly infiltrated subgroups
-
Biomolecular Condensation: A New Phase in Cancer Research. Cancer Discov. (IF 38.272) Pub Date : 2022-07-19 Anupam K Chakravarty,Daniel J McGrail,Thomas M Lozanoski,Brandon S Dunn,David J H Shih,Kara M Cirillo,Sueda H Cetinkaya,Wenjin Jim Zheng,Gordon B Mills,S Stephen Yi,Daniel F Jarosz,Nidhi Sahni
Multicellularity was a watershed development in evolution. However, it also meant that individual cells could escape regulatory mechanisms that restrict proliferation at a severe cost to the organism: cancer. From the standpoint of cellular organization, evolutionary complexity scales to organize different molecules within the intracellular milieu. The recent realization that many biomolecules can
-
Single cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer. Cancer Discov. (IF 38.272) Pub Date : 2022-07-18 Aislyn Schalck,Donastas Sakellariou-Thompson,Marie-Andree Forget,Emi Sei,Tara G Hughes,Alexandre Reuben,Shanshan Bai,Min Hu,Tapsi Kumar,Mark W Hurd,Matthew H G Katz,Ching-Wei D Tzeng,Shubham Pant,Milind Javle,David R Fogelman,Anirban Maitra,Cara L Haymaker,Michael P Kim,Nicholas E Navin,Chantale Bernatchez
Pancreatic ductal adenocarcinoma (PDAC) has few effective treatments. Immunotherapy, an attractive alternative strategy, remains challenging with the lack of knowledge on the tumor-infiltrating lymphocyte (TIL) landscape in PDAC. To generate a reference of T-cell subpopulations, we profiled 80,000 T cells from 57 PDAC, 22 uninvolved/normal samples, and cultured TIL using single-cell transcriptomic
-
Grand Challenge Winners Leveraging Intellectual Diversity. Cancer Discov. (IF 38.272) Pub Date : 2022-07-18
The NCI and Cancer Research UK have unveiled the first four winners of Cancer Grand Challenges awards. The teams will probe cancer cachexia, extrachromosomal DNA, CAR T cells for childhood solid tumors, and possible mechanisms of carcinogenesis. Each team received a 5-year, $25 million grant.
-
Structure of SHOC2-PP1C-RAS Reveals a Mechanism of RAF Activation. Cancer Discov. (IF 38.272) Pub Date : 2022-07-15
Determination of the SHOC2-PP1C-RAS structure uncovers the mechanism of substrate specificity for RAF.
-
Tissue-Resident Memory T Cells Underlie Neoadjuvant Immunotherapy Response. Cancer Discov. (IF 38.272) Pub Date : 2022-07-15
CD8+ T cells that respond to neoadjuvant immunotherapy express tissue-resident memory gene programs.
-
Metastatic Metabolic Plasticity Is Shaped by RNA Methylation Modifications. Cancer Discov. (IF 38.272) Pub Date : 2022-07-15
The m5c and f5c RNA modifications support mitochondrial mRNA translation promoting metastasis.
-
AACR Project GENIE: 100,000 cases and beyond. Cancer Discov. (IF 38.272) Pub Date : 2022-07-12 Trevor J Pugh,Jonathan L Bell,Jeff P Bruce,Gary J Doherty,Matthew Galvin,Michelle F Green,Haley Hunter-Zinck,Priti Kumari,Michele L LeNoue-Newton,Marilyn M Li,James Lindsay,Tali Mazor,Andrea Ovalle,Stephen-John Sammut,Nikolaus Schultz,Thomas V Yu,Shawn M Sweeney,Brady Bernard,Aacr Project Genie Consortium
The American Association for Cancer Research (AACR) Project GENIE is an international pan-cancer registry with the goal to inform cancer research and clinical care worldwide. Founded in late 2015, the milestone GENIE 9.1-public release contains data from >110,000 tumors from >100,000 people treated at 19 cancer centers from USA, Canada, the United Kingdom, France, Netherlands, and Spain. Here, we demonstrate
-
SMYD3 impedes small cell lung cancer sensitivity to alkylation damage through RNF113A methylation-phosphorylation crosstalk. Cancer Discov. (IF 38.272) Pub Date : 2022-07-12 Valentina Lukinovic,Simone Hausmann,Gael S Roth,Clement Oyeniran,Tanveer Ahmad,Ning Tsao,Joshua R Brickner,Alexandre G Casanova,Florent Chuffart,Ana Morales Benitez,Jessica Vayr,Rebecca Rodell,Marianne Tardif,Pascal W T C Jansen,Yohann Coute,Michiel Vermeulen,Pierre Hainaut,Pawel K Mazur,Nima Mosammaparast,Nicolas Reynoird
Small cell lung cancer is the most fatal form of lung cancer, with dismal survival, limited therapeutic options and rapid development of chemoresistance. We identified the lysine methyltransferase SMYD3 as a major regulator of small cell lung cancer (SCLC) sensitivity to alkylation-based chemotherapy. RNF113A methylation by SMYD3 impairs its interaction with the phosphatase PP4, controlling its phosphorylation
-
Oncolytic Viral Therapy Is Feasible in Diffuse Intrinsic Pontine Glioma. Cancer Discov. (IF 38.272) Pub Date : 2022-07-08
Infusion of an oncolytic virus followed by radiotherapy led to responses and prolonged survival in patients with DIPG.
-
GREM1 Restricts Plasticity and Maintains Heterogeneity in Pancreatic Cancer. Cancer Discov. (IF 38.272) Pub Date : 2022-07-08
Pancreatic cancer cellular heterogeneity is enforced via paracrine signaling from mesenchymal cells.
-
Molecular Profiling in Pediatric Cancer Identifies Potential Targeted Therapies. Cancer Discov. (IF 38.272) Pub Date : 2022-07-08
Clinically significant genomic alterations were identified in pediatric tumors using molecular tumor profiling.
-
Walking the Tightrope: Balancing Delicate Inflammation Response to Eradicate Acute Myeloid Leukemia. Cancer Discov. (IF 38.272) Pub Date : 2022-07-06 Alexandre Puissant,Hind Medyouf
Ellegast and colleagues show that monocytic acute myeloid leukemias (AML), enriched in inflammatory and immune gene sets, exploit a transcriptional repressor-namely, IRF2BP2-to mitigate their cell-intrinsic inflammatory output and ensure their maintenance. IRF2BP2 ablation results in heightened inflammatory signals that reach a set point that triggers apoptotic AML cell death in an NF-κB-IL1β-dependent
-
IFNα Potentiates Immune-Checkpoint Blockade by Rewiring Metabolic Cross-talk. Cancer Discov. (IF 38.272) Pub Date : 2022-07-06 Kung-Chi Kao,Alison Jaccard,Ping-Chih Ho
In this issue, Hu and colleagues unveil that IFNα administration combined with anti-PD-1 therapy can potentiate murine and human CD8+ T-cell antitumor response in hepatocellular carcinoma, highlighting a novel therapeutic strategy for hepatocellular carcinoma. See related article by Hu et al., p. 1718 (6) .
-
Inducing Hypermutability to Promote Anti-PD-1 Therapy Response. Cancer Discov. (IF 38.272) Pub Date : 2022-07-06 Jason A Willis,Michael J Overman
The lack of clinical activity from various immune-checkpoint blockade approaches in mismatch repair- proficient (MMRp) colorectal cancer has demonstrated a critical need for novel approaches. In this issue, Crisafulli and colleagues provide proof of concept for the induction of hypermutability through the use of temozolomide as a potential pathway for enabling a productive anti-PD-1 immune response
-
The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discov. (IF 38.272) Pub Date : 2022-07-06 Gilberto Morgan,Neeraj Agarwal,Toni K Choueiri,Don S Dizon,Erika P Hamilton,Merry Jennifer Markham,Mark Lewis,Tatiana M Prowell,Hope S Rugo,Vivek Subbiah,Howard L West
Social media (SoMe) platforms have the ability to strengthen the oncology community, leading to intellectual connections that with time develop into friendships. SoMe has immense potential in all areas of medicine, and SoMe in oncology is proof of this, raising awareness about clinical trials, promoting cancer prevention techniques, amplifying oncology information, enabling diverse viewpoints into
-
FDA Aims to Ban Menthol in Cigarettes. Cancer Discov. (IF 38.272) Pub Date : 2022-07-06
The FDA has proposed a ban on menthol flavoring in cigarettes. If enacted, the prohibition would increase smoking cessation rates and decrease first-time tobacco use, in turn drastically reducing smoking-related cancer deaths.
-
PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry. Cancer Discov. (IF 38.272) Pub Date : 2022-07-05 Amish J Patel,Sarah Warda,Jesper L V Maag,Rohan Misra,Miguel A Miranda-Roman,Mohini R Pachai,Cindy J Lee,Dan Li,Naitao Wang,Gabriella Bayshtok,Eve Fishinevich,Yinuo Meng,Elissa W P Wong,Juan Yan,Emily Giff,Melissa B Pappalardi,Michael T McCabe,Jonathan A Fletcher,Charles M Rudin,Sarat Chandarlapaty,Joseph M Scandura,Richard P Koche,Jacob L Glass,Cristina R Antonescu,Deyou Zheng,Yu Chen,Ping Chi
Polycomb Repressive Complex 2 (PRC2) has oncogenic and tumor suppressor roles in cancer. There is clinical success of targeting this complex in PRC2-dependent cancers, but an unmet therapeutic need exists in PRC2-loss cancer. PRC2 inactivating mutations are a hallmark feature of high-grade malignant peripheral nerve sheath tumor (MPNST), an aggressive sarcoma with poor prognosis and no effective targeted
-
cBAF Components and MYC Cooperate to Determine CD8+ T-cell Fate Decisions. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Low expression of cBAF components and MYC support a pro-memory CD8+ T-cell fate decision.
-
Chromatin Remodeling Factors Drive Epigenetic Changes Crucial for T-cell Exhaustion. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Depleting components of the cBAF chromatin remodeling complex improves antitumor T-cell function.
-
Genome-wide Mutation Rate Modeling Identifies Novel Driver Mutations. Cancer Discov. (IF 38.272) Pub Date : 2022-08-05
Driver mutations were identified in cryptic splice regions, 5' UTRs, and rarely mutated genes.